| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
LY345899 is a novel, potent inhibitor of cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with a Ki of 0.018 μM. LY345899 inhibited MTHFD2 with an IC50 of 663 nM and inhibited MTHFD1 with an IC50 of 96 nM.
| ln Vitro |
MTHFD enzyme in the mitochondria and cytoplasm can be inhibited by LY 345899 [4]. In vitro, LY 345899 may impair anchorage independence, whereas in vivo, it may cause tumor development and metastasis, disturb NADPH and redox balance, and hasten cell death under oxidative stress conditions such hypoxia [4].
|
|---|---|
| ln Vivo |
In vivo studies of LY345899 (ip; 5–10 mg/kg; 5 days/week; 4 weeks) showed strong antitumor activity as well as therapeutic activity against CRC [1].
|
| Animal Protocol |
Animal/Disease Models: BABL/c nude colorectal cancer (CRC) model based on SW620 or PDX [4]
Doses: 5-10 mg/kg Route of Administration: intraperitoneal (ip) injection; 5-10 mg/kg; 5 days/week; 4 Weekly Experimental Results: demonstrated lower cell proliferation index and higher cell apoptosis. No statistically significant weight loss or other signs of acute or delayed toxicity were demonstrated in mice. |
| References |
|
| Molecular Formula |
C20H21N7O7
|
|---|---|
| Molecular Weight |
471.423443555832
|
| Exact Mass |
471.15
|
| CAS # |
10538-99-5
|
| PubChem CID |
135484014
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
986
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C1N(C2C=CC(C(N[C@H](C(=O)O)CCC(=O)O)=O)=CC=2)CC2CNC3=C(C(NC(N)=N3)=O)N21
|
| InChi Key |
JSNFRYBHBVDHSG-KIYNQFGBSA-N
|
| InChi Code |
InChI=1S/C20H21N7O7/c21-19-24-15-14(17(31)25-19)27-11(7-22-15)8-26(20(27)34)10-3-1-9(2-4-10)16(30)23-12(18(32)33)5-6-13(28)29/h1-4,11-12H,5-8H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t11?,12-/m0/s1
|
| Chemical Name |
(4-(3-amino-1-hydroxy-9-oxo-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl)-L-glutamic acid
|
| Synonyms |
LY345899; LY-345899; LY 345899;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~265.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.30 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (4.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1213 mL | 10.6063 mL | 21.2125 mL | |
| 5 mM | 0.4243 mL | 2.1213 mL | 4.2425 mL | |
| 10 mM | 0.2121 mL | 1.0606 mL | 2.1213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA